Return to Clinical Trials Search Results

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)

Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) [Time Frame: Up to approximately 38 months] Overall Survival (OS) [Time Frame: Up to approximately 46 months] Secondary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) at Month 24 Overall Survival (OS) at Month 36 Complete Response (CR) Rate Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) at Week 12 Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Progression-Free Survival (PFS) Per RECIST 1.1 in Programmed Cell Death 1 Ligand (PD-L1) Positive Participants Overall Survival in PD-L1 Positive Participants Progression-Free Survival After Next-Line Treatment (PFS 2) Following Discontinuation of Study Treatment Change from Baseline in EORTC QLQ-C30 Global Health Status Score Change from Baseline in EORTC QLQ-C30 Physical Function Score Change from Baseline EORTC QLQ-CX24 Score Number of Participants Who Experience One or More Adverse Events Number of Participants Who Discontinue Study Treatment Due to and Adverse Event

Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) [Time Frame: Up to approximately 38 months] Overall Survival (OS) [Time Frame: Up to approximately 46 months] Secondary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) at Month 24 Overall Survival (OS) at Month 36 Complete Response (CR) Rate Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) at Week 12 Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Progression-Free Survival (PFS) Per RECIST 1.1 in Programmed Cell Death 1 Ligand (PD-L1) Positive Participants Overall Survival in PD-L1 Positive Participants Progression-Free Survival After Next-Line Treatment (PFS 2) Following Discontinuation of Study Treatment Change from Baseline in EORTC QLQ-C30 Global Health Status Score Change from Baseline in EORTC QLQ-C30 Physical Function Score Change from Baseline EORTC QLQ-CX24 Score Number of Participants Who Experience One or More Adverse Events Number of Participants Who Discontinue Study Treatment Due to and Adverse Event